Roche: results of trial on prostate cancer drug
(CercleFinance.com) - On Friday Roche announced that the IPATential150 Phase III trial met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with metastatic castration-resistant metastatic prostate cancer (mCRPC) with PTEN loss tumours.
In this group of patients, ipatasertib, in combination with abiraterone and prednisone/prednisolone provided a statistically significant reduction in the risk of disease worsening or death, compared to the current standard of care (abiraterone and prednisone/prednisolone) plus placebo.
The other co-primary endpoint of rPFS in the overall study population (ITT) was not met.
The results of the IPATential150 study will be presented at an upcoming medical meeting. The trial will continue until the next planned analysis and data will be shared with health authorities.
Copyright (c) 2020 CercleFinance.com. All rights reserved.